Lumida
/CNMD
⌘K
Conmed Corp

Conmed Corp

CNMD
$49.42USD-0.02%-0.01 today

MARKET CAP

1.5B

P/E (TTM)

10.5x

FWD P/E

11.1x

DAY RANGE

$49 – $50

52W RANGE

$31
$57

AI Summary

Stalk
Buy NowMedium

CNMD remains in a Stage 2 medium-term advance, consolidating just above rising 9EMA and 20EMA after a sharp rally. With no exhaustion signals, neutral RSI, and price holding key EMAs, pullback entries are favorable. A breakout above recent swing highs would extend the trend; a decisive close below the 20EMA would invalidate the bullish posture.

  • Exit of gastroenterology reallocates resources to high-margin AirSeal and BioBrace.
  • Q2 2026 net sales reached $353 M (+6% YoY); adjusted gross margin at 59.5%.
  • Dismal profitability metrics and negative margin revisions highlight returns struggles.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.0B$1.0B$1.2B$1.3B$1.4B
YoY %+17.2%+3.4%+19.1%+5.0%+5.2%
P / Sales4.5x2.6x2.8x1.6x0.9x
EV / Sales5.5x4.0x3.9x2.6x1.8x
Gross Profit, Adj.$568.0M$571.2M$676.2M$733.0M$750.5M
YoY %+23.4%+0.6%+18.4%+8.4%+2.4%
Margin %56.2%54.6%54.3%56.1%54.6%
EV / Gross Profit9.7x7.4x7.3x4.7x3.4x
EBITDA, Adj.$180.5M$139.6M$192.5M$272.2M$176.9M
YoY %+52.1%-22.7%+37.9%+41.4%-35.0%
Margin %17.9%13.4%15.5%20.8%12.9%
EV / EBITDA30.6x30.2x25.5x12.7x14.2x
EBIT$109.7M$70.1M$120.6M$200.3M$102.6M
YoY %+138.5%-36.2%+72.2%+66.1%-48.8%
Margin %10.9%6.7%9.7%15.3%7.5%
EV / EBIT50.4x60.2x40.8x17.2x24.5x
Net Income$62.5M$-80.6M$64.5M$132.4M$47.1M
YoY %+557.2%-228.8%+180.0%+105.4%-64.5%
Net Margin6.2%-7.7%5.2%10.1%3.4%
EPS (GAAP)$1.94-$2.68$2.04$4.25$1.51
YoY %+506.2%-238.1%+176.1%+108.3%-64.5%